Comparison of Postoperative Recovery Quality and Safety Between Anricofen Combined With Ciprofol and Sufentanil Combined With Ciprofol for Non-intubated Anesthesia During ERCP (Anricofen Cipr)
Comparison of Postoperative Recovery Quality and Safety Between Anricofen Combined With Ciprofol and Sufentanil Combined With Ciprofol for Non-intubated Anesthesia During Endoscopic Retrograde Cholangiopancreatography: A Randomized Controlled Trial
This study aims to compare postoperative recovery quality and safety between anricofen combined with ciprofol and sufentanil combined with ciprofol in patients undergoing endoscopic retrograde cholangiopancreatography (ERCP) under non-intubated anesthesia.
This is a single-center, prospective, randomized, controlled study involving patients aged 18-80 years who are scheduled for elective ERCP. A total of 180 participants are planned to be enrolled and randomly assigned in a 1:1 ratio to two groups.
Participants in the anricofen group will receive intravenous anricofen (HSK21542) at a dose of 1 μg/kg before ciprofol induction. Participants in the sufentanil group will receive intravenous sufentanil at a dose of 0.1 μg/kg before ciprofol induction. Both groups will receive ciprofol for anesthesia induction and maintenance.
The primary outcome is the total Quality of Recovery-15 (QoR-15) score at 24 hours after the procedure. Secondary outcomes include postoperative pain scores at different time points, total ciprofol consumption, recovery time, post-anesthesia care unit stay, respiratory and hemodynamic adverse events, postoperative nausea and vomiting, and serious adverse events.
The study is expected to provide clinical evidence on the postoperative recovery quality and safety of these two analgesic regimens for patients undergoing ERCP under non-intubated anesthesia.
調査の概要
研究の種類
入学 (推定)
段階
- 適用できない
連絡先と場所
研究連絡先
- 名前:Longhua Guo
- 電話番号:18303733012
- メール:1535732839@qq.com
研究場所
-
-
Henan
-
Xinxiang、Henan、中国
- 募集
- The First Affiliated Hospital of Henan Medical University
-
-
参加基準
適格基準
就学可能な年齢
健康ボランティアの受け入れ
受講資格のある性別
説明
**Inclusion Criteria:**
- Aged 18 to 80 years;
- American Society of Anesthesiologists (ASA) physical status I to III;
- Patients scheduled to undergo elective endoscopic retrograde cholangiopancreatography (ERCP).
**Exclusion Criteria:**
- Pregnancy or lactation;
- Obstructive sleep apnea (OSA);
- Long-term use of analgesics or psychotropic drugs, or a history of drug abuse;
- Coagulation dysfunction, bleeding tendency, or current anticoagulant therapy;
- Allergy to any of the study drugs;
- Severe cardiac, hepatic, renal, or other major organ diseases;
- Mental or cognitive impairment that prevents cooperation with the assessment;
- Inability to comply with the study protocol or complete follow-up;
- Requirement for tracheal intubation, postoperative transfer to the intensive care unit (ICU), or postoperative pancreatitis.
研究計画
研究はどのように設計されていますか?
デザインの詳細
- 主な目的:処理
- 割り当て:ランダム化
- 介入モデル:並列代入
- マスキング:ダブル
武器と介入
参加者グループ / アーム |
介入・治療 |
|---|---|
|
実験的:Anricofen(HSK21542) 1 μg/kg + Ciprofol
|
Anricofen (HSK21542) is a peripherally restricted κ-opioid receptor agonist. In this study, it is administered intravenously at a dose of 1 μg/kg 3 minutes before ciprofol induction by slow injection. Ciprofol is an intravenous sedative agent used for anesthesia induction and maintenance in this study. It is administered intravenously at an induction dose of 0.3 mg/kg by slow injection over more than 30 seconds. After the Modified Observer's Assessment of Alertness/Sedation (MOAA/S) score reaches 3 or below, ERCP is initiated. Anesthesia is maintained with a continuous infusion of ciprofol at 1.0-2.0 mg/kg/h. If patient movement or eye opening occurs during the procedure, an additional bolus of 0.10-0.15 mg/kg may be administered, with an interval of at least 2 minutes between additional doses. |
|
アクティブコンパレータ:Sufentanil 0.1 μg/kg + Ciprofol
|
Ciprofol is an intravenous sedative agent used for anesthesia induction and maintenance in this study. It is administered intravenously at an induction dose of 0.3 mg/kg by slow injection over more than 30 seconds. After the Modified Observer's Assessment of Alertness/Sedation (MOAA/S) score reaches 3 or below, ERCP is initiated. Anesthesia is maintained with a continuous infusion of ciprofol at 1.0-2.0 mg/kg/h. If patient movement or eye opening occurs during the procedure, an additional bolus of 0.10-0.15 mg/kg may be administered, with an interval of at least 2 minutes between additional doses. Sufentanil is an opioid analgesic. In this study, it is used as the active comparator and administered intravenously at a dose of 0.1 μg/kg 3 minutes before ciprofol induction by slow injection. |
この研究は何を測定していますか?
主要な結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
Quality of Recovery-15 (QoR-15) Score at 24 Hours Postoperatively
時間枠:24 hours after the procedure
|
The primary outcome is the total score of the Quality of Recovery-15 (QoR-15) questionnaire at 24 hours after ERCP. The QoR-15 is a patient-reported measure of postoperative recovery quality, with total scores ranging from 0 to 150. Higher scores indicate better postoperative recovery quality. |
24 hours after the procedure
|
二次結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
Resting Numerical Rating Scale (NRS) Pain Score
時間枠:At prespecified time points postoperatively
|
Resting pain intensity will be assessed using the Numerical Rating Scale (NRS), ranging from 0 (no pain) to 10 (worst imaginable pain), at the prespecified postoperative assessment time points. |
At prespecified time points postoperatively
|
|
Total Ciprofol Consumption
時間枠:During the ERCP procedure
|
The total dose of ciprofol administered to each participant during the ERCP procedure will be recorded and compared between the two groups. |
During the ERCP procedure
|
|
Respiratory and Hemodynamic Adverse Events
時間枠:During the procedure and up to 24 hours postoperatively
|
The incidence and details of perioperative respiratory and hemodynamic adverse events will be recorded. Respiratory events include hypoxemia, apnea or significant hypoventilation, airway interventions, mask-assisted ventilation, supraglottic airway placement, and emergency tracheal intubation. Hemodynamic events include hypotension, bradycardia, and the use of vasoactive drugs such as norepinephrine or atropine. |
During the procedure and up to 24 hours postoperatively
|
|
Postoperative Nausea and Vomiting (PONV)
時間枠:Within 24 hours postoperatively
|
The occurrence of postoperative nausea and vomiting will be recorded and compared between the two groups. |
Within 24 hours postoperatively
|
|
Serious Adverse Events (SAEs)
時間枠:From enrollment until the end of the study
|
The occurrence, type, and details of serious adverse events will be recorded throughout the study period. |
From enrollment until the end of the study
|
|
Recovery Time
時間枠:From the end of the ERCP procedure to recovery
|
The time required for participants to recover from anesthesia after the ERCP procedure will be recorded and compared between the two groups. |
From the end of the ERCP procedure to recovery
|
|
Post-Anesthesia Care Unit (PACU) Length of Stay
時間枠:From PACU admission to PACU discharge
|
The duration of stay in the post-anesthesia care unit (PACU) after the procedure will be recorded and compared between the two groups. |
From PACU admission to PACU discharge
|
協力者と研究者
研究記録日
主要日程の研究
研究開始 (実際)
一次修了 (推定)
研究の完了 (推定)
試験登録日
最初に提出
QC基準を満たした最初の提出物
最初の投稿 (実際)
学習記録の更新
投稿された最後の更新 (実際)
QC基準を満たした最後の更新が送信されました
最終確認日
詳しくは
本研究に関する用語
追加の関連 MeSH 用語
その他の研究ID番号
- XYFY-IIT-ANES-ERCP-2025-01
個々の参加者データ (IPD) の計画
個々の参加者データ (IPD) を共有する予定はありますか?
医薬品およびデバイス情報、研究文書
米国FDA規制医薬品の研究
米国FDA規制機器製品の研究
この情報は、Web サイト clinicaltrials.gov から変更なしで直接取得したものです。研究の詳細を変更、削除、または更新するリクエストがある場合は、register@clinicaltrials.gov。 までご連絡ください。 clinicaltrials.gov に変更が加えられるとすぐに、ウェブサイトでも自動的に更新されます。